Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, FVT

uMETHOD to Present Data from Its RestoreU METHOD at the 2018 Alzheimer's Association International Conference® (AAIC®)


DURHAM, N.C., July 20, 2018 /PRNewswire/ -- uMETHOD Health, a healthcare technology company that provides precision medicine solutions to physicians treating Alzheimer's and other chronic conditions, announced today that the company will present its work across five diverse areas related to cognitive decline and mild Alzheimer's disease at the 2018 Alzheimer's Association International Conference (AAIC) held July 22-26th in Chicago.

The following will be presented at this year's meeting. Authors include Dorothy Keine, MS, and John Q. Walker II, PhD, of uMETHOD, and Marwan N. Sabbagh, MD, who was named Director of the Cleveland Clinic Lou Ruvo Center for Brain Health, effective May 1, 2018:

About the AAIC

The Alzheimer's Association International Conference® (AAIC®) is the largest and most influential international meeting dedicated to advancing dementia science. Each year, AAIC convenes the world's leading basic science and clinical researchers, next-generation investigators, clinicians and the care research community to share research discoveries that will lead to methods of prevention and treatment, and improvements in diagnosis for Alzheimer's disease.

About uMETHOD

uMETHOD's AI platform generates personalized treatment plans for chronic diseases. uMETHOD's RestoreU METHOD treatment plans for Alzheimer's and dementia patients are based on data from the patient's genome, bio-specimens, medical history, demographics, medications, lifestyle and other factors. The company works with physicians across the country and also matches patients with personal coaches to support and encourage program adherence. For more information visit www.umethod.com.

PRESS CONTACT: 
Helen Bertelli, Benecomms
(202) 465-1468, [email protected]

SOURCE uMETHOD Health


These press releases may also interest you

at 07:05
At the ESCMID Global 2024 conference, Bruker is enhancing its innovative diagnostic solutions in microbial identification, antimicrobial susceptibility testing (AST), early sepsis diagnostics, and other infectious disease assays. Simplifying...

at 07:00
Bristol Myers Squibb today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo® (nivolumab) in combination with cisplatin and gemcitabine for the...

at 07:00
R&D Leader and software architect with more than three decades of experience designing, developing,...

at 07:00
Gordian Biotechnology, an in vivo drug discovery and development...

at 07:00
GeBBS Healthcare Solutions, Inc.(ChrysCapital portfolio company) a leading provider of technology enabled Revenue Cycle Management (RCM) & Risk Adjustment Solutions for Healthcare Providers and Payers, announced the acquisition of CCD Health, a...

at 07:00
Many American children...



News published on and distributed by: